{"gene":"ABHD6","run_date":"2026-06-09T22:02:37","timeline":{"discoveries":[{"year":2010,"finding":"ABHD6 is a postsynaptic serine hydrolase that hydrolyzes 2-arachidonoylglycerol (2-AG) and thereby controls its accumulation and efficacy at cannabinoid receptors. In BV-2 microglia, ABHD6 knockdown reduced 2-AG hydrolysis and increased CB2-mediated cell migration; in neurons, selective inhibition led to activity-dependent 2-AG accumulation and enabled CB1-dependent long-term depression by otherwise subthreshold stimulation.","method":"shRNA knockdown in BV-2 cells, pharmacological inhibition in primary neurons and cortical slices, electrophysiology (LTD induction), subcellular fractionation showing postsynaptic localization","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (KD, pharmacological inhibition, electrophysiology, localization), replicated across cell types and labs","pmids":["20657592"],"is_preprint":false},{"year":2012,"finding":"Human ABHD6 is a genuine monoacylglycerol lipase with a catalytic triad comprising S148-D278-H306; site-directed mutagenesis of S148 abolished enzymatic activity and abolished labeling by the active-site serine-directed probe TAMRA-FP. Medium-chain saturated MAGs are the best substrates for hABHD6. Mutations of D278 and H306 abolished activity but also prevented detectable expression, so their direct catalytic roles could not be confirmed.","method":"Site-directed mutagenesis of catalytic triad residues, fluorescent glycerol activity assay, activity-based protein profiling (TAMRA-FP labeling), substrate profiling","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic assay with mutagenesis and active-site probe, single lab with multiple orthogonal methods","pmids":["22969151"],"is_preprint":false},{"year":2013,"finding":"In macrophages, ABHD6 controls 2-AG levels; pharmacological ABHD6 inhibition increases 2-AG, which is oxygenated by COX-2 to produce the anti-inflammatory prostaglandin D2-glycerol ester (PGD2-G). Blocking COX-2 or prostaglandin D synthase prevented the anti-inflammatory effects of ABHD6 inhibition, establishing a pathway: ABHD6 → 2-AG → COX-2 → PGD2-G → anti-inflammatory signaling.","method":"Pharmacological inhibition (ABHD6 inhibitor, COX-2 inhibitor, PGD synthase inhibitor), lipid mass spectrometry, in vivo LPS-inflammation model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — epistasis established by sequential pharmacological blockade, in vitro and in vivo validation, multiple orthogonal methods in one study","pmids":["24101490"],"is_preprint":false},{"year":2014,"finding":"ABHD6 inhibition decreases PTZ-induced seizures through a mechanism involving GABAA receptors (not CB1/CB2), as the antiepileptic effect was retained in Cnr1-/- and Cnr2-/- mice but blocked by a subconvulsive dose of the GABAA antagonist picrotoxin.","method":"Pharmacological inhibition, genetic knockout mice (Cnr1-/-, Cnr2-/-), picrotoxin co-administration, seizure behavioral assays","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in multiple knockout lines combined with pharmacological rescue, rigorous behavioral readout","pmids":["25033180"],"is_preprint":false},{"year":2015,"finding":"ABHD6 degrades bis(monoacylglycero)phosphate (BMP), a late endosomal/lysosomal lipid, with high specific activity. ABHD6 is responsible for ~90% of hepatic BMP hydrolase activity; ABHD6 knockdown increases hepatic BMP levels. Tissue fractionation and live-cell imaging showed ABHD6 co-localizes with late endosomes/lysosomes, and the enzyme is active at cytosolic pH, suggesting it degrades BMP exported from acidic organelles.","method":"BMP hydrolase activity assay, siRNA knockdown with lipidomics, tissue fractionation, live-cell imaging co-localization","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (activity assay, KD + lipidomics, imaging), single lab","pmids":["26491015"],"is_preprint":false},{"year":2015,"finding":"ABHD6 inhibition with WWL70 ameliorates experimental autoimmune encephalomyelitis (EAE) through a CB2 receptor-dependent mechanism: the therapeutic effect was abolished by CB2 antagonist co-administration and absent in CB2 knockout mice, but not affected by CB1 antagonism.","method":"Pharmacological inhibition (WWL70), CB1/CB2 receptor antagonists, CB2 knockout mice, EAE behavioral and histological endpoints","journal":"Neuropharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic (CB2-KO) and pharmacological epistasis, replicated across two approaches; however, later studies questioned ABHD6's specific contribution vs. WWL70 off-targets","pmids":["26189763"],"is_preprint":false},{"year":2016,"finding":"ABHD6 negatively regulates surface delivery and synaptic function of AMPA receptors independent of its hydrolase activity. ABHD6 overexpression reduced GluA1 surface expression and glutamate-induced currents in HEK293T cells expressing GluA1+stargazin; CRISPR/Cas9 knockout or shRNA knockdown in neurons increased AMPAR-mediated transmission. A GFCLIPQ motif in the GluA1 C-terminus is required for this inhibitory effect, and ABHD6 physically binds the C-terminal tail of GluA1.","method":"Overexpression and CRISPR/Cas9 KO in neurons, whole-cell patch-clamp electrophysiology, surface biotinylation, co-immunoprecipitation/pulldown, mutagenesis of GluA1 C-terminus","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (electrophysiology, surface biotinylation, pulldown, mutagenesis, KO and OE), mechanistic dissection of hydrolase-independent function","pmids":["27114538"],"is_preprint":false},{"year":2017,"finding":"ABHD6 suppresses AMPAR-mediated currents and surface expression of GluA2- and GluA3-containing receptors in HEK293T cells; the C-terminal domains of GluA2 and GluA3 are required for ABHD6 binding and for its inhibitory effects. Pulldown experiments confirmed ABHD6 binds GluA1-3, and deletion of GluA C-terminal domains abolishes this binding.","method":"Overexpression in HEK293T cells, whole-cell patch-clamp, surface biotinylation, pulldown assays, C-terminal deletion constructs","journal":"Frontiers in molecular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods (electrophysiology, biochemical pulldown, mutagenesis), single lab, extends prior GluA1 findings to GluA2/3","pmids":["28303090"],"is_preprint":false},{"year":2019,"finding":"Global deletion of ABHD6 increases circulating BMP concentrations in mice, and a human patient with a loss-of-function mutation in ABHD6 shows an altered circulating BMP profile, confirming ABHD6 as a physiologically relevant BMP hydrolase in vivo.","method":"ABHD6 global knockout mice, lipidomics of plasma/liver, human patient with ABHD6 loss-of-function mutation","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO in mice combined with human loss-of-function mutation validation, replicated across species","pmids":["30894461"],"is_preprint":false},{"year":2020,"finding":"Adipose-specific ABHD6 deletion increases 2-MAG levels in visceral WAT under cold stress, which activates PPARα in white adipocytes, leading to elevated expression and activity of glycerolipid/free fatty acid (GL/FFA) cycle enzymes and increased cold tolerance without changes in UCP1.","method":"Adipose-specific ABHD6 KO mice, cold tolerance assay, lipidomics (nuclear 2-MAG), PPARα target gene expression, GL/FFA cycle enzyme activity assays","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — tissue-specific KO with multiple metabolic readouts, single lab, pathway placement via lipid measurements and gene expression","pmids":["33201859"],"is_preprint":false},{"year":2020,"finding":"ABHD6 functions as the primary MAG lipase in NSCLC and acts as an oncogene; ABHD6 silencing reduced cancer cell migration, invasion, and metastasis in vivo, while overexpression promoted malignancy. ABHD6 blockade induced intracellular MAG accumulation and activated PPARα/γ signaling.","method":"siRNA knockdown, ectopic overexpression, xenograft and lung metastasis in vivo models, MAG hydrolase activity assay, PPARα/γ transactivation assay, lipid quantification","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal in vitro and in vivo methods, single lab","pmids":["32143183"],"is_preprint":false},{"year":2020,"finding":"In response to acute psychosocial stress, the epigenetic corepressor LSD1 directly binds the promoter regulatory regions of Abhd6 and Magl to transcriptionally repress them, thereby increasing 2-AG levels and enhancing ECS-mediated synaptic modulation. This negative transcriptional control is lost during chronic stress.","method":"Mouse stress models, gene expression analyses, chromatin immunoprecipitation (ChIP) showing LSD1 binding to Abhd6 and Magl promoters","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP establishes direct epigenetic regulation, coupled with behavioral and gene expression data; single lab","pmids":["32141088"],"is_preprint":false},{"year":2021,"finding":"CPT1C physically interacts with ABHD6 (demonstrated by co-immunoprecipitation and FRET) and negatively regulates ABHD6 hydrolase activity, thereby modulating 2-AG signaling through CB1 receptors. CPT1C-KO mouse brains show increased ABHD6 activity. This regulation is dependent on CPT1C's malonyl-CoA sensing: fasting (which reduces brain malonyl-CoA) increases ABHD6 activity in hypothalamus of WT but not CPT1C-KO mice.","method":"Co-immunoprecipitation, FRET assay, fluorescent ABHD6 activity assay in cells and brain tissues, CPT1C-KO mice, cAMP assay for CB1 signaling","journal":"British journal of pharmacology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus FRET plus functional activity assays in KO tissue, multiple orthogonal methods in one study","pmids":["33444462"],"is_preprint":false},{"year":2023,"finding":"ABHD6 activity controls extrasynaptic (tonic) GABAAR currents in dentate granule cells, but not synaptic (phasic) currents. Heterozygous Abhd6 mutation and pharmacological ABHD6 inhibition reduced thermally induced seizures and premature lethality in Scn1a+/- (Dravet syndrome) mice through GABAAR potentiation.","method":"Abhd6+/- genetic mouse model crossed with Scn1a+/-, pharmacological inhibition, brain slice electrophysiology measuring tonic and phasic GABAAR currents","journal":"Neurobiology of disease","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — electrophysiology directly demonstrates GABAAR current modulation, combined with genetic model; single lab but multiple orthogonal methods","pmids":["36990366"],"is_preprint":false},{"year":2023,"finding":"ABHD6 is required for neuronal activity-dependent endocytosis of surface AMPARs independent of its hydrolase activity. ABHD6 KO mice show impaired hippocampal LTD and synaptic downscaling, with deficits in reversal learning. ABHD6 KO selectively enhanced AMPAR-mediated basal synaptic responses and surface AMPAR expression.","method":"ABHD6 KO mice, electrophysiology (LTD, mEPSC), AMPAR internalization assays, surface biotinylation, behavioral reversal learning","journal":"Progress in neurobiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — constitutive KO combined with electrophysiology, internalization assays, and behavioral phenotype; multiple orthogonal methods; mechanistic dissection of hydrolase-independent function","pmids":["38159878"],"is_preprint":false},{"year":2024,"finding":"Loss of ABHD6 in nucleus accumbens (postsynaptic) neurons, but not in ventral tegmental area (presynaptic) neurons, completely prevents diet-induced obesity in male mice, reduces food- and drug-seeking, and attenuates inhibitory synaptic transmission onto medium spiny neurons. Intraventricular infusion of an ABHD6 inhibitor also restrains appetite and promotes weight loss.","method":"Region-specific viral ABHD6 knockdown/knockout (three viral approaches), electrophysiology (inhibitory synaptic transmission), behavioral assays, intraventricular pharmacology","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — three independent viral approaches with circuit-specific resolution, electrophysiology, and pharmacological convergence; single lab but multiple rigorous methods","pmids":["39681558"],"is_preprint":false},{"year":2025,"finding":"ABHD6 is identified as a major lysophosphatidylserine (lyso-PS) lipase in the mammalian liver and kidneys (distinct from ABHD12, which controls lyso-PS in the brain). Pharmacological inhibition of ABHD6 validates its lyso-PS lipase activity in vivo, and ABHD6 is functionally designated as the major lyso-PS lipase in primary hepatocytes, mouse liver, and kidneys.","method":"In vitro inhibitor screen against membrane fractions of multiple tissues, pharmacological validation in vivo, primary hepatocyte assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical activity assay plus in vivo pharmacological validation, single lab","pmids":["39761854"],"is_preprint":false},{"year":2026,"finding":"Lactylation of ABHD6 at K245 (driven by Warburg-effect-elevated lactate in lenvatinib-resistant HCC) triggers mitochondrial translocation of ABHD6, where it acts as a scaffold binding FIS1 and displacing DRP1, thereby stabilizing hyperfused mitochondria and conferring drug resistance. This function is independent of catalysis but requires an unoccupied S148 catalytic site; inhibitors that occupy S148 or block lactate production prevent ABHD6-FIS1 complex formation and restore lenvatinib sensitivity.","method":"K245 lactylation identification, mitochondrial fractionation, co-immunoprecipitation of ABHD6-FIS1 complex, DRP1 displacement assay, catalytic site mutagenesis, pharmacological occupancy of S148, in vitro and in vivo resistance models","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, fractionation, mutagenesis, and pharmacological rescue in one study; single lab; novel PTM and non-canonical function not yet independently replicated","pmids":["41861279"],"is_preprint":false},{"year":2023,"finding":"ABHD6 suppression in macrophages under nutrient excess leads to accumulation of 2-MAG species that activate PPAR signaling, promoting anti-inflammatory (M2/MMe) macrophage polarization over pro-inflammatory (M1) polarization. KT203 inhibition or ABHD6-KO in MMe-polarized macrophages attenuated pro-inflammatory cytokines and upregulated lipid metabolism genes via PPARs.","method":"ABHD6-KO mice, pharmacological inhibition (KT203), flow cytometry of adipose tissue macrophages, cytokine measurement, lipidomics of cellular and secreted MAG species, PPAR target gene expression","journal":"Molecular metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO plus pharmacological confirmation, lipidomics pathway placement, single lab","pmids":["37838014"],"is_preprint":false},{"year":2024,"finding":"ABHD6 regulates AMPAR gating kinetics in a TARP γ-2-dependent manner: in the presence of TARP γ-2 (but not alone), ABHD6 accelerates deactivation and desensitization of GluA1 and GluA2(Q)-containing homomeric and GluA1/GluA2(R)/GluA3(R) heteromeric receptors, and slows recovery from desensitization of GluA1 flip isoform. ABHD6-KO neurons displayed slower deactivation and desensitization.","method":"Outside-out patch recording with ultra-fast glutamate application in HEK293T cells expressing various AMPAR/TARP/ABHD6 combinations; ABHD6-KO neurons","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — rigorous electrophysiological method (outside-out patches, ultra-fast application) with multiple receptor combinations and KO neurons; preprint, not yet peer-reviewed","pmids":[],"is_preprint":true}],"current_model":"ABHD6 is a postsynaptic, membrane-bound serine hydrolase with a catalytic triad (S148-D278-H306) that hydrolyzes multiple lipid substrates including 2-arachidonoylglycerol (2-AG), monoacylglycerols, bis(monoacylglycero)phosphate (BMP), and lysophosphatidylserine, thereby regulating endocannabinoid signaling (controlling CB1/CB2 receptor activation, tonic GABAAR currents, and LTD), lysosomal lipid sorting, and innate immune/metabolic signaling through MAG/PPAR pathways; additionally, independent of its hydrolase activity, ABHD6 functions as an AMPAR auxiliary subunit that physically binds GluA1-3 C-terminal tails to suppress AMPAR surface delivery, promote AMPAR endocytosis, and (in the presence of TARP γ-2) accelerate AMPAR gating kinetics, while its activity is regulated by CPT1C interaction and malonyl-CoA sensing and, in cancer contexts, by K245 lactylation that converts it into a mitochondrial scaffold disrupting DRP1-FIS1-dependent fission."},"narrative":{"mechanistic_narrative":"ABHD6 is a membrane-bound serine hydrolase that shapes lipid signaling across neuronal, immune, and metabolic compartments while doubling as a hydrolase-independent regulator of glutamate receptor trafficking [PMID:20657592, PMID:27114538]. Its catalytic triad centers on S148, with D278 and H306 completing an active site whose integrity is required for activity and for active-site probe labeling [PMID:22969151]. As a 2-arachidonoylglycerol (2-AG) hydrolase, it limits endocannabinoid tone: inhibition raises activity-dependent 2-AG to enable CB1-dependent long-term depression and CB2-mediated microglial migration, and routes 2-AG toward COX-2-derived anti-inflammatory PGD2-glycerol esters [PMID:20657592, PMID:24101490]. ABHD6 also degrades the lysosomal lipid bis(monoacylglycero)phosphate (BMP), accounting for most hepatic BMP hydrolase activity, with loss of function altering circulating BMP in mice and humans [PMID:26491015, PMID:30894461], and serves as a major lysophosphatidylserine lipase in liver and kidney [PMID:39761854]. Through control of monoacylglycerol (MAG) pools it gates PPARα/γ signaling governing adipose thermogenesis, macrophage polarization, and NSCLC malignancy [PMID:33201859, PMID:32143183, PMID:37838014]. In the brain it controls extrasynaptic tonic GABA_A receptor currents and, through a separable non-catalytic function, binds the C-terminal tails of GluA1–3 to suppress AMPAR surface delivery, drive activity-dependent AMPAR endocytosis, and—together with TARP γ-2—tune AMPAR gating, thereby supporting hippocampal LTD and synaptic downscaling [PMID:27114538, PMID:36990366, PMID:38159878]. Its hydrolase activity is restrained by malonyl-CoA-sensing CPT1C, and in lenvatinib-resistant hepatocellular carcinoma K245 lactylation redirects ABHD6 to mitochondria where it scaffolds FIS1 and displaces DRP1 to suppress fission [PMID:33444462, PMID:41861279]. Genetic and pharmacological loss of ABHD6 is protective in models of seizure, Dravet syndrome, autoimmune neuroinflammation, and diet-induced obesity [PMID:25033180, PMID:26189763, PMID:36990366, PMID:39681558].","teleology":[{"year":2010,"claim":"Established ABHD6 as a postsynaptic 2-AG hydrolase that sets endocannabinoid tone, answering whether 2-AG degradation is enzyme-controlled at synapses and in microglia.","evidence":"shRNA knockdown in BV-2 microglia, pharmacological inhibition with electrophysiology in neurons/slices, subcellular fractionation","pmids":["20657592"],"confidence":"High","gaps":["Did not define the catalytic residues","Substrate scope beyond 2-AG unaddressed"]},{"year":2012,"claim":"Defined the catalytic machinery, confirming ABHD6 as a bona fide monoacylglycerol lipase with an S148-centered active site.","evidence":"Site-directed mutagenesis of S148/D278/H306, fluorescent glycerol assay, TAMRA-FP activity-based labeling, substrate profiling","pmids":["22969151"],"confidence":"High","gaps":["Catalytic roles of D278 and H306 unconfirmed due to loss of expression","In vitro substrate ranking may not reflect cellular preference"]},{"year":2013,"claim":"Connected ABHD6 substrate control to downstream eicosanoid signaling, showing 2-AG it spares is oxygenated by COX-2 into anti-inflammatory PGD2-G.","evidence":"Sequential pharmacological blockade (ABHD6, COX-2, PGD synthase), lipid mass spectrometry, in vivo LPS inflammation","pmids":["24101490"],"confidence":"High","gaps":["Receptor target of PGD2-G not identified","Macrophage-specific contribution vs systemic not resolved"]},{"year":2014,"claim":"Revealed a CB-receptor-independent antiepileptic mechanism, implicating GABA_A receptor signaling downstream of ABHD6 inhibition.","evidence":"Pharmacological inhibition in Cnr1-/- and Cnr2-/- mice with picrotoxin co-administration, seizure behavior","pmids":["25033180"],"confidence":"High","gaps":["Molecular link from ABHD6 lipid product to GABA_A currents undefined","Cell type mediating the effect not pinpointed"]},{"year":2015,"claim":"Identified ABHD6 as a dominant BMP hydrolase, expanding its substrate range beyond MAGs into lysosomal lipid catabolism.","evidence":"BMP hydrolase assay, siRNA knockdown with lipidomics, tissue fractionation, live-cell imaging co-localization with late endosomes/lysosomes","pmids":["26491015"],"confidence":"High","gaps":["How cytosolic ABHD6 accesses organelle-derived BMP not mechanistically shown","Physiological consequences of BMP accumulation not tested here"]},{"year":2015,"claim":"Tested ABHD6 inhibition in autoimmune neuroinflammation, attributing therapeutic benefit to CB2 signaling.","evidence":"WWL70 inhibition with CB1/CB2 antagonists and CB2-KO mice in EAE","pmids":["26189763"],"confidence":"Medium","gaps":["WWL70 off-target effects complicate ABHD6 attribution","Single inhibitor without genetic ABHD6 loss"]},{"year":2016,"claim":"Uncovered a hydrolase-independent role: ABHD6 physically binds the GluA1 C-terminus to suppress AMPAR surface delivery, decoupling its enzymatic and synaptic functions.","evidence":"Overexpression and CRISPR KO in neurons, patch-clamp, surface biotinylation, pulldown, GFCLIPQ motif mutagenesis","pmids":["27114538"],"confidence":"High","gaps":["Mechanism by which binding blocks delivery not defined","Whether the interaction is direct or scaffolded not fully resolved"]},{"year":2017,"claim":"Generalized the AMPAR interaction across subunits, showing ABHD6 binds GluA2 and GluA3 C-terminal domains to suppress their surface expression.","evidence":"HEK293T overexpression, patch-clamp, surface biotinylation, pulldown with C-terminal deletions","pmids":["28303090"],"confidence":"Medium","gaps":["Subunit selectivity in native neurons not addressed","Single heterologous system"]},{"year":2019,"claim":"Validated ABHD6 as a physiologically relevant BMP hydrolase across species using genetic and human loss-of-function evidence.","evidence":"ABHD6 global KO mice with plasma/liver lipidomics, human loss-of-function patient","pmids":["30894461"],"confidence":"High","gaps":["Clinical phenotype of altered BMP not characterized","Tissue source of circulating BMP unresolved"]},{"year":2020,"claim":"Placed ABHD6 upstream of PPAR-driven metabolic and oncogenic programs via control of MAG pools in adipose, lung cancer, and macrophages.","evidence":"Tissue-specific and global KO, overexpression, lipidomics, PPAR target/transactivation assays, xenograft and cold-tolerance models","pmids":["33201859","32143183","37838014"],"confidence":"Medium","gaps":["Which MAG species directly engage PPARs not defined","Direct vs indirect PPAR activation not established"]},{"year":2020,"claim":"Identified transcriptional regulation of ABHD6 by the corepressor LSD1 during acute psychosocial stress, linking epigenetic control to endocannabinoid tone.","evidence":"Mouse stress models, gene expression, ChIP of LSD1 at Abhd6/Magl promoters","pmids":["32141088"],"confidence":"Medium","gaps":["LSD1 cofactors at the Abhd6 promoter unknown","Loss of repression in chronic stress mechanistically unexplained"]},{"year":2021,"claim":"Defined post-translational/allosteric control of ABHD6 activity through CPT1C and malonyl-CoA sensing, coupling metabolic state to 2-AG/CB1 signaling.","evidence":"Reciprocal Co-IP, FRET, fluorescent activity assays in CPT1C-KO brain, cAMP CB1 assay, fasting manipulation","pmids":["33444462"],"confidence":"High","gaps":["Structural basis of CPT1C-mediated inhibition unknown","Whether interaction modulates non-2AG substrates untested"]},{"year":2023,"claim":"Distinguished ABHD6 control of tonic versus phasic inhibition and demonstrated therapeutic benefit in Dravet syndrome via GABA_A potentiation.","evidence":"Abhd6+/- crossed with Scn1a+/-, inhibitor pharmacology, brain-slice electrophysiology of tonic/phasic GABA_A currents","pmids":["36990366"],"confidence":"High","gaps":["Lipid product linking ABHD6 to extrasynaptic GABA_A receptors not identified","Granule-cell specificity vs other circuits not mapped"]},{"year":2023,"claim":"Showed ABHD6 is required for activity-dependent AMPAR endocytosis, LTD, and synaptic downscaling, establishing its non-catalytic role in plasticity and learning.","evidence":"ABHD6 KO mice, electrophysiology (LTD, mEPSC), AMPAR internalization assays, surface biotinylation, reversal learning","pmids":["38159878"],"confidence":"High","gaps":["Endocytic machinery recruited by ABHD6 unidentified","Relationship to its lipid substrates not resolved"]},{"year":2024,"claim":"Localized a behaviorally decisive ABHD6 function to nucleus accumbens postsynaptic neurons controlling diet-induced obesity and reward-seeking.","evidence":"Three region-specific viral KD/KO approaches, electrophysiology of inhibitory transmission, behavior, intraventricular pharmacology","pmids":["39681558"],"confidence":"High","gaps":["Substrate/pathway mediating MSN effect not defined","Hydrolase vs AMPAR-scaffold contribution to phenotype unseparated"]},{"year":2024,"claim":"Refined the AMPAR role by showing ABHD6 modulates gating kinetics conditionally on TARP γ-2, positioning it as an auxiliary subunit affecting receptor biophysics.","evidence":"Outside-out patches with ultra-fast glutamate application across AMPAR/TARP/ABHD6 combinations and ABHD6-KO neurons (preprint)","pmids":[],"confidence":"Medium","gaps":["Preprint, not yet peer-reviewed","Structural basis of the TARP-dependent effect unknown"]},{"year":2025,"claim":"Extended the substrate range to lysophosphatidylserine, designating ABHD6 the major lyso-PS lipase in liver and kidney distinct from brain ABHD12.","evidence":"Inhibitor screen against tissue membrane fractions, in vivo pharmacological validation, primary hepatocyte assays","pmids":["39761854"],"confidence":"Medium","gaps":["Downstream lyso-PS signaling consequences untested","Genetic confirmation in vivo not provided"]},{"year":2026,"claim":"Revealed a lactylation-driven moonlighting function in which mitochondrial ABHD6 scaffolds FIS1, displaces DRP1, and confers cancer drug resistance independent of catalysis.","evidence":"K245 lactylation mapping, mitochondrial fractionation, ABHD6-FIS1 Co-IP, DRP1 displacement, S148 mutagenesis/occupancy, in vitro/in vivo resistance models","pmids":["41861279"],"confidence":"Medium","gaps":["Single lab, not independently replicated","How an unoccupied S148 enables scaffolding unexplained","Lactyltransferase responsible not identified"]},{"year":null,"claim":"It remains unresolved how ABHD6's distinct catalytic activities, its non-catalytic AMPAR-scaffolding function, and its lactylation-dependent mitochondrial role are integrated within a single protein and selected between in different cell types.","evidence":"No single study reconciles the hydrolase, auxiliary-subunit, and scaffold functions","pmids":[],"confidence":"Low","gaps":["No structure of full-length ABHD6 with binding partners","Determinants directing ABHD6 to membrane substrates vs AMPAR vs mitochondria unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[1,4,16]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[1,4]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[6,14,19]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[6,17]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[6,7]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[4]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[4]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[17]}],"pathway":[{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[0,13,14]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[4,9,16]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,18]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,12]}],"complexes":[],"partners":["GRIA1","GRIA2","GRIA3","CPT1C","FIS1","CACNG2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9BV23","full_name":"Monoacylglycerol lipase ABHD6","aliases":["2-arachidonoylglycerol hydrolase","Abhydrolase domain-containing protein 6"],"length_aa":337,"mass_kda":38.3,"function":"Lipase that preferentially hydrolysis medium-chain saturated monoacylglycerols including 2-arachidonoylglycerol (PubMed:22969151). Through 2-arachidonoylglycerol degradation may regulate endocannabinoid signaling pathways (By similarity). Also has a lysophosphatidyl lipase activity with a preference for lysophosphatidylglycerol among other lysophospholipids (By similarity). Also able to degrade bis(monoacylglycero)phosphate (BMP) and constitutes the major enzyme for BMP catabolism (PubMed:26491015). BMP, also known as lysobisphosphatidic acid, is enriched in late endosomes and lysosomes and plays a key role in the formation of intraluminal vesicles and in lipid sorting (PubMed:26491015)","subcellular_location":"Late endosome membrane; Lysosome membrane; Mitochondrion membrane","url":"https://www.uniprot.org/uniprotkb/Q9BV23/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ABHD6","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ABHD6","total_profiled":1310},"omim":[{"mim_id":"616966","title":"ABHYDROLASE DOMAIN-CONTAINING PROTEIN 6, ACYLGLYCEROL LIPASE; ABHD6","url":"https://www.omim.org/entry/616966"},{"mim_id":"613599","title":"ABHYDROLASE DOMAIN-CONTAINING PROTEIN 12, LYSOPHOSPHOLIPASE; ABHD12","url":"https://www.omim.org/entry/613599"},{"mim_id":"609699","title":"MONOGLYCERIDE LIPASE; MGLL","url":"https://www.omim.org/entry/609699"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":60.7}],"url":"https://www.proteinatlas.org/search/ABHD6"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q9BV23","domains":[{"cath_id":"3.40.50.1820","chopping":"47-335","consensus_level":"high","plddt":92.7144,"start":47,"end":335},{"cath_id":"1.20.5","chopping":"1-34","consensus_level":"medium","plddt":75.3291,"start":1,"end":34}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BV23","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BV23-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BV23-F1-predicted_aligned_error_v6.png","plddt_mean":90.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ABHD6","jax_strain_url":"https://www.jax.org/strain/search?query=ABHD6"},"sequence":{"accession":"Q9BV23","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BV23.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BV23/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BV23"}},"corpus_meta":[{"pmid":"20657592","id":"PMC_20657592","title":"The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors.","date":"2010","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/20657592","citation_count":356,"is_preprint":false},{"pmid":"21418147","id":"PMC_21418147","title":"The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors.","date":"2011","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21418147","citation_count":221,"is_preprint":false},{"pmid":"22969151","id":"PMC_22969151","title":"Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).","date":"2012","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/22969151","citation_count":150,"is_preprint":false},{"pmid":"24101490","id":"PMC_24101490","title":"Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24101490","citation_count":132,"is_preprint":false},{"pmid":"25033180","id":"PMC_25033180","title":"ABHD6 blockade exerts antiepileptic activity in PTZ-induced seizures and in spontaneous seizures in R6/2 mice.","date":"2014","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/25033180","citation_count":95,"is_preprint":false},{"pmid":"28880480","id":"PMC_28880480","title":"Monoacylglycerol signalling and ABHD6 in health and disease.","date":"2017","source":"Diabetes, obesity & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28880480","citation_count":77,"is_preprint":false},{"pmid":"24152295","id":"PMC_24152295","title":"Discovery and optimization of piperidyl-1,2,3-triazole ureas as potent, selective, and in vivo-active inhibitors of α/β-hydrolase domain containing 6 (ABHD6).","date":"2013","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24152295","citation_count":66,"is_preprint":false},{"pmid":"26189763","id":"PMC_26189763","title":"Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis.","date":"2015","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26189763","citation_count":64,"is_preprint":false},{"pmid":"27114538","id":"PMC_27114538","title":"α/β-Hydrolase domain-containing 6 (ABHD6) negatively regulates the surface delivery and synaptic function of AMPA receptors.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27114538","citation_count":59,"is_preprint":false},{"pmid":"30853109","id":"PMC_30853109","title":"ABHD6: Its Place in Endocannabinoid Signaling and Beyond.","date":"2019","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30853109","citation_count":48,"is_preprint":false},{"pmid":"26491015","id":"PMC_26491015","title":"α/β Hydrolase Domain-containing 6 (ABHD6) Degrades the Late Endosomal/Lysosomal Lipid Bis(monoacylglycero)phosphate.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26491015","citation_count":48,"is_preprint":false},{"pmid":"30894461","id":"PMC_30894461","title":"Metabolic disease and ABHD6 alter the circulating bis(monoacylglycerol)phosphate profile in mice and humans.","date":"2019","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/30894461","citation_count":41,"is_preprint":false},{"pmid":"18360779","id":"PMC_18360779","title":"An unannotated alpha/beta hydrolase superfamily member, ABHD6 differentially expressed among cancer cell lines.","date":"2008","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/18360779","citation_count":36,"is_preprint":false},{"pmid":"33201859","id":"PMC_33201859","title":"Adipose ABHD6 regulates tolerance to cold and thermogenic programs.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/33201859","citation_count":34,"is_preprint":false},{"pmid":"30075103","id":"PMC_30075103","title":"Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.","date":"2018","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30075103","citation_count":34,"is_preprint":false},{"pmid":"26350245","id":"PMC_26350245","title":"Comparative molecular field analysis and molecular dynamics studies of α/β hydrolase domain containing 6 (ABHD6) inhibitors.","date":"2015","source":"Journal of molecular modeling","url":"https://pubmed.ncbi.nlm.nih.gov/26350245","citation_count":31,"is_preprint":false},{"pmid":"32143183","id":"PMC_32143183","title":"Enhanced monoacylglycerol lipolysis by ABHD6 promotes NSCLC pathogenesis.","date":"2020","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/32143183","citation_count":28,"is_preprint":false},{"pmid":"19793082","id":"PMC_19793082","title":"High expression of the evolutionarily conserved alpha/beta hydrolase domain containing 6 (ABHD6) in Ewing tumors.","date":"2009","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/19793082","citation_count":27,"is_preprint":false},{"pmid":"28086912","id":"PMC_28086912","title":"WWL70 attenuates PGE2 production derived from 2-arachidonoylglycerol in microglia by ABHD6-independent mechanism.","date":"2017","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/28086912","citation_count":26,"is_preprint":false},{"pmid":"25504894","id":"PMC_25504894","title":"Optimization of 1,2,5-thiadiazole carbamates as potent and selective ABHD6 inhibitors.","date":"2014","source":"ChemMedChem","url":"https://pubmed.ncbi.nlm.nih.gov/25504894","citation_count":26,"is_preprint":false},{"pmid":"24534757","id":"PMC_24534757","title":"PXK locus in systemic lupus erythematosus: fine mapping and functional analysis reveals novel susceptibility gene ABHD6.","date":"2014","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/24534757","citation_count":23,"is_preprint":false},{"pmid":"33450278","id":"PMC_33450278","title":"The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity.","date":"2021","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33450278","citation_count":20,"is_preprint":false},{"pmid":"32141088","id":"PMC_32141088","title":"Termination of acute stress response by the endocannabinoid system is regulated through lysine-specific demethylase 1-mediated transcriptional repression of 2-AG hydrolases ABHD6 and MAGL.","date":"2020","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32141088","citation_count":20,"is_preprint":false},{"pmid":"30564946","id":"PMC_30564946","title":"Structural properties and role of the endocannabinoid lipases ABHD6 and ABHD12 in lipid signalling and disease.","date":"2018","source":"Amino acids","url":"https://pubmed.ncbi.nlm.nih.gov/30564946","citation_count":18,"is_preprint":false},{"pmid":"37287623","id":"PMC_37287623","title":"ABHD6 and MAGL control 2-AG levels in the PAG and allodynia in a CSD-induced periorbital model of headache.","date":"2023","source":"Frontiers in pain research (Lausanne, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/37287623","citation_count":18,"is_preprint":false},{"pmid":"36238196","id":"PMC_36238196","title":"Semaglutide May Alleviate Hepatic Steatosis in T2DM Combined with NFALD Mice via miR-5120/ABHD6.","date":"2022","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/36238196","citation_count":17,"is_preprint":false},{"pmid":"30171986","id":"PMC_30171986","title":"Re-examining the potential of targeting ABHD6 in multiple sclerosis: Efficacy of systemic and peripherally restricted inhibitors in experimental autoimmune encephalomyelitis.","date":"2018","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30171986","citation_count":17,"is_preprint":false},{"pmid":"28303090","id":"PMC_28303090","title":"The Inhibitory Effect of α/β-Hydrolase Domain-Containing 6 (ABHD6) on the Surface Targeting of GluA2- and GluA3-Containing AMPA Receptors.","date":"2017","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/28303090","citation_count":17,"is_preprint":false},{"pmid":"36005632","id":"PMC_36005632","title":"α/β-Hydrolase Domain-Containing 6 (ABHD6)- A Multifunctional Lipid Hydrolase.","date":"2022","source":"Metabolites","url":"https://pubmed.ncbi.nlm.nih.gov/36005632","citation_count":16,"is_preprint":false},{"pmid":"32829065","id":"PMC_32829065","title":"Impact of tetrahydrocannabinol on the endocannabinoid 2-arachidonoylglycerol metabolism: ABHD6 and ABHD12 as novel players in human placenta.","date":"2020","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/32829065","citation_count":16,"is_preprint":false},{"pmid":"33444462","id":"PMC_33444462","title":"Carnitine palmitoyltransferase 1C negatively regulates the endocannabinoid hydrolase ABHD6 in mice, depending on nutritional status.","date":"2021","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33444462","citation_count":13,"is_preprint":false},{"pmid":"32371333","id":"PMC_32371333","title":"Therapeutic potential of targeting α/β-Hydrolase domain-containing 6 (ABHD6).","date":"2020","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32371333","citation_count":10,"is_preprint":false},{"pmid":"30950828","id":"PMC_30950828","title":"Pseudomonas aeruginosa esterase PA2949, a bacterial homolog of the human membrane esterase ABHD6: expression, purification and crystallization.","date":"2019","source":"Acta crystallographica. Section F, Structural biology communications","url":"https://pubmed.ncbi.nlm.nih.gov/30950828","citation_count":10,"is_preprint":false},{"pmid":"23110439","id":"PMC_23110439","title":"Highly predictive ligand-based pharmacophore and homology models of ABHD6.","date":"2012","source":"Chemical biology & drug design","url":"https://pubmed.ncbi.nlm.nih.gov/23110439","citation_count":10,"is_preprint":false},{"pmid":"39546192","id":"PMC_39546192","title":"Mesenchymal Stem Cell-Derived Extracellular Vesicles Carrying Circ-Tulp4 Attenuate Diabetes Mellitus with Nonalcoholic Fatty Liver Disease by Inhibiting Cell Pyroptosis through the HNRNPC/ABHD6 Axis.","date":"2024","source":"Tissue engineering and regenerative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39546192","citation_count":9,"is_preprint":false},{"pmid":"30108813","id":"PMC_30108813","title":"Chiral disubstituted piperidinyl ureas: a class of dual diacylglycerol lipase-α and ABHD6 inhibitors.","date":"2017","source":"MedChemComm","url":"https://pubmed.ncbi.nlm.nih.gov/30108813","citation_count":8,"is_preprint":false},{"pmid":"37838014","id":"PMC_37838014","title":"ABHD6 suppression promotes anti-inflammatory polarization of adipose tissue macrophages via 2-monoacylglycerol/PPAR signaling in obese mice.","date":"2023","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37838014","citation_count":7,"is_preprint":false},{"pmid":"39761854","id":"PMC_39761854","title":"Identification of ABHD6 as a lysophosphatidylserine lipase in the mammalian liver and kidneys.","date":"2025","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39761854","citation_count":7,"is_preprint":false},{"pmid":"26344596","id":"PMC_26344596","title":"Revisiting 1,3,4-Oxadiazol-2-ones: Utilization in the Development of ABHD6 Inhibitors.","date":"2015","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26344596","citation_count":7,"is_preprint":false},{"pmid":"39681558","id":"PMC_39681558","title":"ABHD6 loss-of-function in mesoaccumbens postsynaptic but not presynaptic neurons prevents diet-induced obesity in male mice.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39681558","citation_count":6,"is_preprint":false},{"pmid":"38159878","id":"PMC_38159878","title":"ABHD6 drives endocytosis of AMPA receptors to regulate synaptic plasticity and learning flexibility.","date":"2023","source":"Progress in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/38159878","citation_count":5,"is_preprint":false},{"pmid":"40269679","id":"PMC_40269679","title":"Inhibition of endocannabinoid hydrolases MAGL, FAAH and ABHD6 by AKU-005 reduces ex vivo cortical spreading depression.","date":"2025","source":"The journal of headache and pain","url":"https://pubmed.ncbi.nlm.nih.gov/40269679","citation_count":5,"is_preprint":false},{"pmid":"27245903","id":"PMC_27245903","title":"A Sensitive and Versatile Fluorescent Activity Assay for ABHD6.","date":"2016","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/27245903","citation_count":5,"is_preprint":false},{"pmid":"40886915","id":"PMC_40886915","title":"Suppression of adipocyte ABHD6 favors anti-inflammatory and adipogenic programs to preserve adipose tissue fitness in obesity.","date":"2025","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/40886915","citation_count":4,"is_preprint":false},{"pmid":"36990366","id":"PMC_36990366","title":"The serine hydrolase ABHD6 controls survival and thermally induced seizures in a mouse model of Dravet syndrome.","date":"2023","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/36990366","citation_count":3,"is_preprint":false},{"pmid":"36516997","id":"PMC_36516997","title":"Utilizing PET and MALDI Imaging for Discovery of a Targeted Probe for Brain Endocannabinoid α/β-Hydrolase Domain 6 (ABHD6).","date":"2022","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36516997","citation_count":3,"is_preprint":false},{"pmid":"38197491","id":"PMC_38197491","title":"ABHD6 suppresses colorectal cancer progression via AKT signaling pathway.","date":"2024","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/38197491","citation_count":2,"is_preprint":false},{"pmid":"41061850","id":"PMC_41061850","title":"ABHD6 suppression attenuates pro-inflammatory responses in mice and promotes anti-inflammatory polarization of macrophages during endotoxin stress.","date":"2025","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/41061850","citation_count":1,"is_preprint":false},{"pmid":"37720694","id":"PMC_37720694","title":"ABHD6 Inhibition Rescues a Sex-Dependent Deficit in Motor Coordination in The HdhQ200/200 Mouse Model of Huntington's Disease.","date":"2021","source":"Journal of neurology and neurological disorders","url":"https://pubmed.ncbi.nlm.nih.gov/37720694","citation_count":1,"is_preprint":false},{"pmid":"41861279","id":"PMC_41861279","title":"Lactylation Converts ABHD6 into a Mitochondrial Regulator that Drives Lenvatinib Resistance in Hepatocellular Carcinoma.","date":"2026","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/41861279","citation_count":0,"is_preprint":false},{"pmid":"40766524","id":"PMC_40766524","title":"The Lipid Hydrolase ABHD6 is a Therapeutic Target in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Related Hepatocellular Carcinoma.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/40766524","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.05.08.652735","title":"Reduced triacylglycerols and lipid droplets are associated with resilience to Alzheimer’s disease","date":"2025-05-14","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.08.652735","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.06.20.599978","title":"α/β-Hydrolase domain-containing 6 (ABHD6) accelerates the desensitization and deactivation of TARP γ-2-containing AMPA receptors","date":"2024-06-25","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.20.599978","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":30071,"output_tokens":5613,"usd":0.087204,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14242,"output_tokens":5561,"usd":0.105118,"stage2_stop_reason":"end_turn"},"total_usd":0.192322,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"ABHD6 is a postsynaptic serine hydrolase that hydrolyzes 2-arachidonoylglycerol (2-AG) and thereby controls its accumulation and efficacy at cannabinoid receptors. In BV-2 microglia, ABHD6 knockdown reduced 2-AG hydrolysis and increased CB2-mediated cell migration; in neurons, selective inhibition led to activity-dependent 2-AG accumulation and enabled CB1-dependent long-term depression by otherwise subthreshold stimulation.\",\n      \"method\": \"shRNA knockdown in BV-2 cells, pharmacological inhibition in primary neurons and cortical slices, electrophysiology (LTD induction), subcellular fractionation showing postsynaptic localization\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (KD, pharmacological inhibition, electrophysiology, localization), replicated across cell types and labs\",\n      \"pmids\": [\"20657592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Human ABHD6 is a genuine monoacylglycerol lipase with a catalytic triad comprising S148-D278-H306; site-directed mutagenesis of S148 abolished enzymatic activity and abolished labeling by the active-site serine-directed probe TAMRA-FP. Medium-chain saturated MAGs are the best substrates for hABHD6. Mutations of D278 and H306 abolished activity but also prevented detectable expression, so their direct catalytic roles could not be confirmed.\",\n      \"method\": \"Site-directed mutagenesis of catalytic triad residues, fluorescent glycerol activity assay, activity-based protein profiling (TAMRA-FP labeling), substrate profiling\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic assay with mutagenesis and active-site probe, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"22969151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In macrophages, ABHD6 controls 2-AG levels; pharmacological ABHD6 inhibition increases 2-AG, which is oxygenated by COX-2 to produce the anti-inflammatory prostaglandin D2-glycerol ester (PGD2-G). Blocking COX-2 or prostaglandin D synthase prevented the anti-inflammatory effects of ABHD6 inhibition, establishing a pathway: ABHD6 → 2-AG → COX-2 → PGD2-G → anti-inflammatory signaling.\",\n      \"method\": \"Pharmacological inhibition (ABHD6 inhibitor, COX-2 inhibitor, PGD synthase inhibitor), lipid mass spectrometry, in vivo LPS-inflammation model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis established by sequential pharmacological blockade, in vitro and in vivo validation, multiple orthogonal methods in one study\",\n      \"pmids\": [\"24101490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ABHD6 inhibition decreases PTZ-induced seizures through a mechanism involving GABAA receptors (not CB1/CB2), as the antiepileptic effect was retained in Cnr1-/- and Cnr2-/- mice but blocked by a subconvulsive dose of the GABAA antagonist picrotoxin.\",\n      \"method\": \"Pharmacological inhibition, genetic knockout mice (Cnr1-/-, Cnr2-/-), picrotoxin co-administration, seizure behavioral assays\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in multiple knockout lines combined with pharmacological rescue, rigorous behavioral readout\",\n      \"pmids\": [\"25033180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ABHD6 degrades bis(monoacylglycero)phosphate (BMP), a late endosomal/lysosomal lipid, with high specific activity. ABHD6 is responsible for ~90% of hepatic BMP hydrolase activity; ABHD6 knockdown increases hepatic BMP levels. Tissue fractionation and live-cell imaging showed ABHD6 co-localizes with late endosomes/lysosomes, and the enzyme is active at cytosolic pH, suggesting it degrades BMP exported from acidic organelles.\",\n      \"method\": \"BMP hydrolase activity assay, siRNA knockdown with lipidomics, tissue fractionation, live-cell imaging co-localization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (activity assay, KD + lipidomics, imaging), single lab\",\n      \"pmids\": [\"26491015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ABHD6 inhibition with WWL70 ameliorates experimental autoimmune encephalomyelitis (EAE) through a CB2 receptor-dependent mechanism: the therapeutic effect was abolished by CB2 antagonist co-administration and absent in CB2 knockout mice, but not affected by CB1 antagonism.\",\n      \"method\": \"Pharmacological inhibition (WWL70), CB1/CB2 receptor antagonists, CB2 knockout mice, EAE behavioral and histological endpoints\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic (CB2-KO) and pharmacological epistasis, replicated across two approaches; however, later studies questioned ABHD6's specific contribution vs. WWL70 off-targets\",\n      \"pmids\": [\"26189763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ABHD6 negatively regulates surface delivery and synaptic function of AMPA receptors independent of its hydrolase activity. ABHD6 overexpression reduced GluA1 surface expression and glutamate-induced currents in HEK293T cells expressing GluA1+stargazin; CRISPR/Cas9 knockout or shRNA knockdown in neurons increased AMPAR-mediated transmission. A GFCLIPQ motif in the GluA1 C-terminus is required for this inhibitory effect, and ABHD6 physically binds the C-terminal tail of GluA1.\",\n      \"method\": \"Overexpression and CRISPR/Cas9 KO in neurons, whole-cell patch-clamp electrophysiology, surface biotinylation, co-immunoprecipitation/pulldown, mutagenesis of GluA1 C-terminus\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (electrophysiology, surface biotinylation, pulldown, mutagenesis, KO and OE), mechanistic dissection of hydrolase-independent function\",\n      \"pmids\": [\"27114538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ABHD6 suppresses AMPAR-mediated currents and surface expression of GluA2- and GluA3-containing receptors in HEK293T cells; the C-terminal domains of GluA2 and GluA3 are required for ABHD6 binding and for its inhibitory effects. Pulldown experiments confirmed ABHD6 binds GluA1-3, and deletion of GluA C-terminal domains abolishes this binding.\",\n      \"method\": \"Overexpression in HEK293T cells, whole-cell patch-clamp, surface biotinylation, pulldown assays, C-terminal deletion constructs\",\n      \"journal\": \"Frontiers in molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods (electrophysiology, biochemical pulldown, mutagenesis), single lab, extends prior GluA1 findings to GluA2/3\",\n      \"pmids\": [\"28303090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Global deletion of ABHD6 increases circulating BMP concentrations in mice, and a human patient with a loss-of-function mutation in ABHD6 shows an altered circulating BMP profile, confirming ABHD6 as a physiologically relevant BMP hydrolase in vivo.\",\n      \"method\": \"ABHD6 global knockout mice, lipidomics of plasma/liver, human patient with ABHD6 loss-of-function mutation\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO in mice combined with human loss-of-function mutation validation, replicated across species\",\n      \"pmids\": [\"30894461\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Adipose-specific ABHD6 deletion increases 2-MAG levels in visceral WAT under cold stress, which activates PPARα in white adipocytes, leading to elevated expression and activity of glycerolipid/free fatty acid (GL/FFA) cycle enzymes and increased cold tolerance without changes in UCP1.\",\n      \"method\": \"Adipose-specific ABHD6 KO mice, cold tolerance assay, lipidomics (nuclear 2-MAG), PPARα target gene expression, GL/FFA cycle enzyme activity assays\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific KO with multiple metabolic readouts, single lab, pathway placement via lipid measurements and gene expression\",\n      \"pmids\": [\"33201859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ABHD6 functions as the primary MAG lipase in NSCLC and acts as an oncogene; ABHD6 silencing reduced cancer cell migration, invasion, and metastasis in vivo, while overexpression promoted malignancy. ABHD6 blockade induced intracellular MAG accumulation and activated PPARα/γ signaling.\",\n      \"method\": \"siRNA knockdown, ectopic overexpression, xenograft and lung metastasis in vivo models, MAG hydrolase activity assay, PPARα/γ transactivation assay, lipid quantification\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal in vitro and in vivo methods, single lab\",\n      \"pmids\": [\"32143183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In response to acute psychosocial stress, the epigenetic corepressor LSD1 directly binds the promoter regulatory regions of Abhd6 and Magl to transcriptionally repress them, thereby increasing 2-AG levels and enhancing ECS-mediated synaptic modulation. This negative transcriptional control is lost during chronic stress.\",\n      \"method\": \"Mouse stress models, gene expression analyses, chromatin immunoprecipitation (ChIP) showing LSD1 binding to Abhd6 and Magl promoters\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP establishes direct epigenetic regulation, coupled with behavioral and gene expression data; single lab\",\n      \"pmids\": [\"32141088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CPT1C physically interacts with ABHD6 (demonstrated by co-immunoprecipitation and FRET) and negatively regulates ABHD6 hydrolase activity, thereby modulating 2-AG signaling through CB1 receptors. CPT1C-KO mouse brains show increased ABHD6 activity. This regulation is dependent on CPT1C's malonyl-CoA sensing: fasting (which reduces brain malonyl-CoA) increases ABHD6 activity in hypothalamus of WT but not CPT1C-KO mice.\",\n      \"method\": \"Co-immunoprecipitation, FRET assay, fluorescent ABHD6 activity assay in cells and brain tissues, CPT1C-KO mice, cAMP assay for CB1 signaling\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus FRET plus functional activity assays in KO tissue, multiple orthogonal methods in one study\",\n      \"pmids\": [\"33444462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ABHD6 activity controls extrasynaptic (tonic) GABAAR currents in dentate granule cells, but not synaptic (phasic) currents. Heterozygous Abhd6 mutation and pharmacological ABHD6 inhibition reduced thermally induced seizures and premature lethality in Scn1a+/- (Dravet syndrome) mice through GABAAR potentiation.\",\n      \"method\": \"Abhd6+/- genetic mouse model crossed with Scn1a+/-, pharmacological inhibition, brain slice electrophysiology measuring tonic and phasic GABAAR currents\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — electrophysiology directly demonstrates GABAAR current modulation, combined with genetic model; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"36990366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ABHD6 is required for neuronal activity-dependent endocytosis of surface AMPARs independent of its hydrolase activity. ABHD6 KO mice show impaired hippocampal LTD and synaptic downscaling, with deficits in reversal learning. ABHD6 KO selectively enhanced AMPAR-mediated basal synaptic responses and surface AMPAR expression.\",\n      \"method\": \"ABHD6 KO mice, electrophysiology (LTD, mEPSC), AMPAR internalization assays, surface biotinylation, behavioral reversal learning\",\n      \"journal\": \"Progress in neurobiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — constitutive KO combined with electrophysiology, internalization assays, and behavioral phenotype; multiple orthogonal methods; mechanistic dissection of hydrolase-independent function\",\n      \"pmids\": [\"38159878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Loss of ABHD6 in nucleus accumbens (postsynaptic) neurons, but not in ventral tegmental area (presynaptic) neurons, completely prevents diet-induced obesity in male mice, reduces food- and drug-seeking, and attenuates inhibitory synaptic transmission onto medium spiny neurons. Intraventricular infusion of an ABHD6 inhibitor also restrains appetite and promotes weight loss.\",\n      \"method\": \"Region-specific viral ABHD6 knockdown/knockout (three viral approaches), electrophysiology (inhibitory synaptic transmission), behavioral assays, intraventricular pharmacology\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — three independent viral approaches with circuit-specific resolution, electrophysiology, and pharmacological convergence; single lab but multiple rigorous methods\",\n      \"pmids\": [\"39681558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ABHD6 is identified as a major lysophosphatidylserine (lyso-PS) lipase in the mammalian liver and kidneys (distinct from ABHD12, which controls lyso-PS in the brain). Pharmacological inhibition of ABHD6 validates its lyso-PS lipase activity in vivo, and ABHD6 is functionally designated as the major lyso-PS lipase in primary hepatocytes, mouse liver, and kidneys.\",\n      \"method\": \"In vitro inhibitor screen against membrane fractions of multiple tissues, pharmacological validation in vivo, primary hepatocyte assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical activity assay plus in vivo pharmacological validation, single lab\",\n      \"pmids\": [\"39761854\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Lactylation of ABHD6 at K245 (driven by Warburg-effect-elevated lactate in lenvatinib-resistant HCC) triggers mitochondrial translocation of ABHD6, where it acts as a scaffold binding FIS1 and displacing DRP1, thereby stabilizing hyperfused mitochondria and conferring drug resistance. This function is independent of catalysis but requires an unoccupied S148 catalytic site; inhibitors that occupy S148 or block lactate production prevent ABHD6-FIS1 complex formation and restore lenvatinib sensitivity.\",\n      \"method\": \"K245 lactylation identification, mitochondrial fractionation, co-immunoprecipitation of ABHD6-FIS1 complex, DRP1 displacement assay, catalytic site mutagenesis, pharmacological occupancy of S148, in vitro and in vivo resistance models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, fractionation, mutagenesis, and pharmacological rescue in one study; single lab; novel PTM and non-canonical function not yet independently replicated\",\n      \"pmids\": [\"41861279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ABHD6 suppression in macrophages under nutrient excess leads to accumulation of 2-MAG species that activate PPAR signaling, promoting anti-inflammatory (M2/MMe) macrophage polarization over pro-inflammatory (M1) polarization. KT203 inhibition or ABHD6-KO in MMe-polarized macrophages attenuated pro-inflammatory cytokines and upregulated lipid metabolism genes via PPARs.\",\n      \"method\": \"ABHD6-KO mice, pharmacological inhibition (KT203), flow cytometry of adipose tissue macrophages, cytokine measurement, lipidomics of cellular and secreted MAG species, PPAR target gene expression\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO plus pharmacological confirmation, lipidomics pathway placement, single lab\",\n      \"pmids\": [\"37838014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ABHD6 regulates AMPAR gating kinetics in a TARP γ-2-dependent manner: in the presence of TARP γ-2 (but not alone), ABHD6 accelerates deactivation and desensitization of GluA1 and GluA2(Q)-containing homomeric and GluA1/GluA2(R)/GluA3(R) heteromeric receptors, and slows recovery from desensitization of GluA1 flip isoform. ABHD6-KO neurons displayed slower deactivation and desensitization.\",\n      \"method\": \"Outside-out patch recording with ultra-fast glutamate application in HEK293T cells expressing various AMPAR/TARP/ABHD6 combinations; ABHD6-KO neurons\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — rigorous electrophysiological method (outside-out patches, ultra-fast application) with multiple receptor combinations and KO neurons; preprint, not yet peer-reviewed\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"ABHD6 is a postsynaptic, membrane-bound serine hydrolase with a catalytic triad (S148-D278-H306) that hydrolyzes multiple lipid substrates including 2-arachidonoylglycerol (2-AG), monoacylglycerols, bis(monoacylglycero)phosphate (BMP), and lysophosphatidylserine, thereby regulating endocannabinoid signaling (controlling CB1/CB2 receptor activation, tonic GABAAR currents, and LTD), lysosomal lipid sorting, and innate immune/metabolic signaling through MAG/PPAR pathways; additionally, independent of its hydrolase activity, ABHD6 functions as an AMPAR auxiliary subunit that physically binds GluA1-3 C-terminal tails to suppress AMPAR surface delivery, promote AMPAR endocytosis, and (in the presence of TARP γ-2) accelerate AMPAR gating kinetics, while its activity is regulated by CPT1C interaction and malonyl-CoA sensing and, in cancer contexts, by K245 lactylation that converts it into a mitochondrial scaffold disrupting DRP1-FIS1-dependent fission.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ABHD6 is a membrane-bound serine hydrolase that shapes lipid signaling across neuronal, immune, and metabolic compartments while doubling as a hydrolase-independent regulator of glutamate receptor trafficking [#0, #6]. Its catalytic triad centers on S148, with D278 and H306 completing an active site whose integrity is required for activity and for active-site probe labeling [#1]. As a 2-arachidonoylglycerol (2-AG) hydrolase, it limits endocannabinoid tone: inhibition raises activity-dependent 2-AG to enable CB1-dependent long-term depression and CB2-mediated microglial migration, and routes 2-AG toward COX-2-derived anti-inflammatory PGD2-glycerol esters [#0, #2]. ABHD6 also degrades the lysosomal lipid bis(monoacylglycero)phosphate (BMP), accounting for most hepatic BMP hydrolase activity, with loss of function altering circulating BMP in mice and humans [#4, #8], and serves as a major lysophosphatidylserine lipase in liver and kidney [#16]. Through control of monoacylglycerol (MAG) pools it gates PPARα/γ signaling governing adipose thermogenesis, macrophage polarization, and NSCLC malignancy [#9, #10, #18]. In the brain it controls extrasynaptic tonic GABA_A receptor currents and, through a separable non-catalytic function, binds the C-terminal tails of GluA1–3 to suppress AMPAR surface delivery, drive activity-dependent AMPAR endocytosis, and—together with TARP γ-2—tune AMPAR gating, thereby supporting hippocampal LTD and synaptic downscaling [#6, #13, #14]. Its hydrolase activity is restrained by malonyl-CoA-sensing CPT1C, and in lenvatinib-resistant hepatocellular carcinoma K245 lactylation redirects ABHD6 to mitochondria where it scaffolds FIS1 and displaces DRP1 to suppress fission [#12, #17]. Genetic and pharmacological loss of ABHD6 is protective in models of seizure, Dravet syndrome, autoimmune neuroinflammation, and diet-induced obesity [#3, #5, #13, #15].\",\n  \"teleology\": [\n    {\n      \"year\": 2010,\n      \"claim\": \"Established ABHD6 as a postsynaptic 2-AG hydrolase that sets endocannabinoid tone, answering whether 2-AG degradation is enzyme-controlled at synapses and in microglia.\",\n      \"evidence\": \"shRNA knockdown in BV-2 microglia, pharmacological inhibition with electrophysiology in neurons/slices, subcellular fractionation\",\n      \"pmids\": [\"20657592\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the catalytic residues\", \"Substrate scope beyond 2-AG unaddressed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined the catalytic machinery, confirming ABHD6 as a bona fide monoacylglycerol lipase with an S148-centered active site.\",\n      \"evidence\": \"Site-directed mutagenesis of S148/D278/H306, fluorescent glycerol assay, TAMRA-FP activity-based labeling, substrate profiling\",\n      \"pmids\": [\"22969151\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalytic roles of D278 and H306 unconfirmed due to loss of expression\", \"In vitro substrate ranking may not reflect cellular preference\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Connected ABHD6 substrate control to downstream eicosanoid signaling, showing 2-AG it spares is oxygenated by COX-2 into anti-inflammatory PGD2-G.\",\n      \"evidence\": \"Sequential pharmacological blockade (ABHD6, COX-2, PGD synthase), lipid mass spectrometry, in vivo LPS inflammation\",\n      \"pmids\": [\"24101490\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor target of PGD2-G not identified\", \"Macrophage-specific contribution vs systemic not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Revealed a CB-receptor-independent antiepileptic mechanism, implicating GABA_A receptor signaling downstream of ABHD6 inhibition.\",\n      \"evidence\": \"Pharmacological inhibition in Cnr1-/- and Cnr2-/- mice with picrotoxin co-administration, seizure behavior\",\n      \"pmids\": [\"25033180\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link from ABHD6 lipid product to GABA_A currents undefined\", \"Cell type mediating the effect not pinpointed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified ABHD6 as a dominant BMP hydrolase, expanding its substrate range beyond MAGs into lysosomal lipid catabolism.\",\n      \"evidence\": \"BMP hydrolase assay, siRNA knockdown with lipidomics, tissue fractionation, live-cell imaging co-localization with late endosomes/lysosomes\",\n      \"pmids\": [\"26491015\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How cytosolic ABHD6 accesses organelle-derived BMP not mechanistically shown\", \"Physiological consequences of BMP accumulation not tested here\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Tested ABHD6 inhibition in autoimmune neuroinflammation, attributing therapeutic benefit to CB2 signaling.\",\n      \"evidence\": \"WWL70 inhibition with CB1/CB2 antagonists and CB2-KO mice in EAE\",\n      \"pmids\": [\"26189763\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"WWL70 off-target effects complicate ABHD6 attribution\", \"Single inhibitor without genetic ABHD6 loss\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Uncovered a hydrolase-independent role: ABHD6 physically binds the GluA1 C-terminus to suppress AMPAR surface delivery, decoupling its enzymatic and synaptic functions.\",\n      \"evidence\": \"Overexpression and CRISPR KO in neurons, patch-clamp, surface biotinylation, pulldown, GFCLIPQ motif mutagenesis\",\n      \"pmids\": [\"27114538\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which binding blocks delivery not defined\", \"Whether the interaction is direct or scaffolded not fully resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Generalized the AMPAR interaction across subunits, showing ABHD6 binds GluA2 and GluA3 C-terminal domains to suppress their surface expression.\",\n      \"evidence\": \"HEK293T overexpression, patch-clamp, surface biotinylation, pulldown with C-terminal deletions\",\n      \"pmids\": [\"28303090\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Subunit selectivity in native neurons not addressed\", \"Single heterologous system\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Validated ABHD6 as a physiologically relevant BMP hydrolase across species using genetic and human loss-of-function evidence.\",\n      \"evidence\": \"ABHD6 global KO mice with plasma/liver lipidomics, human loss-of-function patient\",\n      \"pmids\": [\"30894461\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Clinical phenotype of altered BMP not characterized\", \"Tissue source of circulating BMP unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placed ABHD6 upstream of PPAR-driven metabolic and oncogenic programs via control of MAG pools in adipose, lung cancer, and macrophages.\",\n      \"evidence\": \"Tissue-specific and global KO, overexpression, lipidomics, PPAR target/transactivation assays, xenograft and cold-tolerance models\",\n      \"pmids\": [\"33201859\", \"32143183\", \"37838014\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Which MAG species directly engage PPARs not defined\", \"Direct vs indirect PPAR activation not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified transcriptional regulation of ABHD6 by the corepressor LSD1 during acute psychosocial stress, linking epigenetic control to endocannabinoid tone.\",\n      \"evidence\": \"Mouse stress models, gene expression, ChIP of LSD1 at Abhd6/Magl promoters\",\n      \"pmids\": [\"32141088\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"LSD1 cofactors at the Abhd6 promoter unknown\", \"Loss of repression in chronic stress mechanistically unexplained\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined post-translational/allosteric control of ABHD6 activity through CPT1C and malonyl-CoA sensing, coupling metabolic state to 2-AG/CB1 signaling.\",\n      \"evidence\": \"Reciprocal Co-IP, FRET, fluorescent activity assays in CPT1C-KO brain, cAMP CB1 assay, fasting manipulation\",\n      \"pmids\": [\"33444462\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of CPT1C-mediated inhibition unknown\", \"Whether interaction modulates non-2AG substrates untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Distinguished ABHD6 control of tonic versus phasic inhibition and demonstrated therapeutic benefit in Dravet syndrome via GABA_A potentiation.\",\n      \"evidence\": \"Abhd6+/- crossed with Scn1a+/-, inhibitor pharmacology, brain-slice electrophysiology of tonic/phasic GABA_A currents\",\n      \"pmids\": [\"36990366\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Lipid product linking ABHD6 to extrasynaptic GABA_A receptors not identified\", \"Granule-cell specificity vs other circuits not mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed ABHD6 is required for activity-dependent AMPAR endocytosis, LTD, and synaptic downscaling, establishing its non-catalytic role in plasticity and learning.\",\n      \"evidence\": \"ABHD6 KO mice, electrophysiology (LTD, mEPSC), AMPAR internalization assays, surface biotinylation, reversal learning\",\n      \"pmids\": [\"38159878\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endocytic machinery recruited by ABHD6 unidentified\", \"Relationship to its lipid substrates not resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Localized a behaviorally decisive ABHD6 function to nucleus accumbens postsynaptic neurons controlling diet-induced obesity and reward-seeking.\",\n      \"evidence\": \"Three region-specific viral KD/KO approaches, electrophysiology of inhibitory transmission, behavior, intraventricular pharmacology\",\n      \"pmids\": [\"39681558\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate/pathway mediating MSN effect not defined\", \"Hydrolase vs AMPAR-scaffold contribution to phenotype unseparated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Refined the AMPAR role by showing ABHD6 modulates gating kinetics conditionally on TARP γ-2, positioning it as an auxiliary subunit affecting receptor biophysics.\",\n      \"evidence\": \"Outside-out patches with ultra-fast glutamate application across AMPAR/TARP/ABHD6 combinations and ABHD6-KO neurons (preprint)\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, not yet peer-reviewed\", \"Structural basis of the TARP-dependent effect unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Extended the substrate range to lysophosphatidylserine, designating ABHD6 the major lyso-PS lipase in liver and kidney distinct from brain ABHD12.\",\n      \"evidence\": \"Inhibitor screen against tissue membrane fractions, in vivo pharmacological validation, primary hepatocyte assays\",\n      \"pmids\": [\"39761854\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream lyso-PS signaling consequences untested\", \"Genetic confirmation in vivo not provided\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Revealed a lactylation-driven moonlighting function in which mitochondrial ABHD6 scaffolds FIS1, displaces DRP1, and confers cancer drug resistance independent of catalysis.\",\n      \"evidence\": \"K245 lactylation mapping, mitochondrial fractionation, ABHD6-FIS1 Co-IP, DRP1 displacement, S148 mutagenesis/occupancy, in vitro/in vivo resistance models\",\n      \"pmids\": [\"41861279\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, not independently replicated\", \"How an unoccupied S148 enables scaffolding unexplained\", \"Lactyltransferase responsible not identified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how ABHD6's distinct catalytic activities, its non-catalytic AMPAR-scaffolding function, and its lactylation-dependent mitochondrial role are integrated within a single protein and selected between in different cell types.\",\n      \"evidence\": \"No single study reconciles the hydrolase, auxiliary-subunit, and scaffold functions\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structure of full-length ABHD6 with binding partners\", \"Determinants directing ABHD6 to membrane substrates vs AMPAR vs mitochondria unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [1, 4, 16]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [1, 4]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [6, 14, 19]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [6, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6, 7]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [0, 13, 14]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [4, 9, 16]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 18]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 12]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"GRIA1\", \"GRIA2\", \"GRIA3\", \"CPT1C\", \"FIS1\", \"CACNG2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}